Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 5 for:    IMU-838
Previous Study | Return to List | Next Study

IMU-838 and Oseltamivir in the Treatment of COVID-19 (IONIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04516915
Recruitment Status : Recruiting
First Posted : August 18, 2020
Last Update Posted : August 21, 2020
Sponsor:
Collaborators:
Immunic AG
University of Warwick
MODEPHARMA
Information provided by (Responsible Party):
University Hospitals Coventry and Warwickshire NHS Trust

Brief Summary:
To evaluate whether time-to-improvement is significantly better in IMU-838 plus Oseltamivir (IONIC Intervention) and standard care vs. Oseltamivir and standard care in adult subjects with coronavirus disease (COVID-19)

Condition or disease Intervention/treatment Phase
Covid 19 Drug: IMU-838 Drug: Oseltamivir Phase 2

Detailed Description:

The IONIC Protocol describes an overarching trial design to provide reliable evidence on the efficacy of IMU-838 (vidofludimus calcium) when delivered in combination with an antiviral therapy (Oseltamivir) [IONIC Intervention] for confirmed or suspected COVID-19 infection in adult patients receiving usual standard of care.

At present, there are no known treatments for COVID-19. Whilst, the anticipated scale of the epidemic is such that hospitals, and particularly intensive care facilities, may be massively overstretched. As described by a few models of pandemic spread, up to 50% of the adult population may fall sick over a period of 8-12 weeks, of whom around 10% may require hospitalisation. This figure could imply nearly 2 million hospital admissions. Considering this scenario, therapies which may only have a moderate impact on survival or on hospital resources could be worthwhile.

Critically, the present trial design has been developed with consideration of the front-line hospital staff working within an overstretched care system in these unprecedented times. To minimise their burden the protocol is deliberately flexible so that it is suitable for a wide range of settings, allowing:

  • a broad range of patients to be enrolled (patient pathway, disease stage or mode of diagnosis)
  • Additional sub-studies may be added to provide more detailed information on side effects or sub-categorisation of patient types but these are not the primary objective and are not required for participation.
  • To be able to include more sites: the investigators will initiate the trial as a single centre (UHCW) and more sites invited to participate according to the emerging evidence
  • The investigator have included 'Exploratory and Secondary objectives' in the protocol however, in consideration of the circumstances the research activities will emulate investigations performed as per standard care/routines care to minimise any burden on the delivery teams.

This is a Phase 2b, randomised, parallel-group, open-label study to assess the efficacy and safety of an oral dose of IMU-838 (22.5 mg twice daily [45 mg/day]) plus Oseltamivir (75mg twice daily [150mg/day]) (IONIC Intervetion) or Oseltamivir alone (75mg twice daily) in hospitalised patients with COVID-19.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Prospective, Randomized, Parallel-Group, Open-Label Study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination With Oseltamivir, in Adults With COVID-19
Actual Study Start Date : June 15, 2020
Estimated Primary Completion Date : May 2021
Estimated Study Completion Date : July 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Oseltamivir

Arm Intervention/treatment
Experimental: IMU-838 + Oseltamivir
Loading dose of IMU-838 followed by 22.5mg BID plus Oseltamivir (75mg BID) for 14 days
Drug: IMU-838
IMU-838 twice daily at 22.5mg doses for 14 days
Other Name: Intervention Arm

Drug: Oseltamivir
Oseltamivir twice daily at 75mg doses for 14 days
Other Name: Control arm

Active Comparator: Oseltamivir
Oseltamivir (75mg BID) for 14 days
Drug: Oseltamivir
Oseltamivir twice daily at 75mg doses for 14 days
Other Name: Control arm




Primary Outcome Measures :
  1. To evaluate whether time-to-improvement is significantly better in IMU-838 plus Oseltamivir (IONIC Intervention) vs. Oseltamivir alone in adult subjects with COVID-19 [ Time Frame: 14 days ]
    Time-to-clinical improvement; defined as the time from randomisation to a 2-point improvement on the world health organizations 9-point ordinal scale (ranging from 0-8; 0 being no evidence of clinical infection and 8 being death), discharge from hospital, or death (whichever occurs first)


Secondary Outcome Measures :
  1. To evaluate safety (number of adverse events) and tolerability (laboratory abnormalities) of IMU 838 + Oseltamivir vs. Oseltamivir alone in adult subjects with COVID-19. [ Time Frame: 28 days ]
    Incidence of Adverse events (AEs) and serious adverse events (SAEs), including COVID-19 worsening and incidence of laboratory abnormalities (defined as a 1.5x increase in liver function test results (total protein, albumin, bilirubin, alkaline phosphotase and ALT) from screening).

  2. To determine the effects of IONIC Intervention on improvement of at least two points in clinical status scale (from 0 to 8; with 8 being no evidence of clinical infection and 8 being death) [ Time Frame: 28 days ]
    Proportion of patients with two-point change on WHO ordinal scale at Day 7 and 28

  3. To assess the effects of IONIC Intervention vs. Oseltamivir on the need for invasive ventilation, renal replacement therapy or ECMO [ Time Frame: 14 days ]
    Proportion of patients free of invasive ventilation, renal replacement therapy or ECMO at Day 7 and 14

  4. To assess the effects of IONIC Intervention vs. Oseltamivir on the length of hospital and intensive care unit (ICU) stay [ Time Frame: 28 days ]
    To assess the effects of IONIC Intervention vs. Oseltamivir on the length of hospital and intensive care unit (ICU) stay

  5. To assess the effects of IONIC Intervention vs. Oseltamivir on the time from treatment initiation to death [ Time Frame: 28 days ]
    Mortality at day 28 and time from treatment initiation to death



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1. Male or non-pregnant female patients at least 18 years old 2. Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection, either:

    • Confirmed cases: prospective participants who test positive to a validated specific SARS-CoV-2 nucleic acid test or has the virus identified by electron microscopy or viral culture, as per local trust policy ≤ 7 days before randomisation.
    • Probable/Suspected case: prospective participants who may have been in contact with a confirmed case of COVID-19, AND have mild to severe COVID-19 clinical symptoms AND radio-graphic evidence* of pulmonary infiltrates consistent with COVID-19 disease 3. Moderate to severe COVID-19 requiring hospitalisation defined as: a) Clinical status category 3-5 (inclusive) on the 7-point clinical status category scale as proposed by the World Health Organisation (WHO) master protocol: I. Category 3: hospitalized, no oxygen therapy II. Category 4: hospitalized, oxygen by mask or nasal prongs III. Category 5: hospitalized, non-invasive ventilation or high-flow oxygen *where routinely available, no tests will be requested for research purpose

Exclusion Criteria

Therapy Exclusion Criteria:

Use of the following concomitant medications is prohibited at Screening Visit and throughout the duration of the trial:

  1. Use of Oseltamivir for more than 48 hrs prior to the first treatment dose
  2. Use of antiviral drugs (e.g. nucleoside analogue reverse-transcriptase inhibitors, protease inhibitors, etc.)
  3. History of long-term or concurrent use of mycophenolate mofetil, methotrexate exceeding 17.5 mg weekly
  4. Chloroquine or hydroxychloroquine
  5. Any medication known to significantly increase urinary elimination of uric acid, in particular lesinurad as well as uricosuric drugs such as probenecid
  6. Treatments for any malignancy, in particular irinotecan, paclitaxel, tretinoin, bosutinib, sorafinib, enasidenib, erlotinib, regorafenib, pazopanib and nilotinib
  7. Any drug significantly restricting water diuresis, in particular vasopressin and vasopressin analogues
  8. Use of rosuvastatin at daily doses higher than 10 mg

Medical History of Concomitant Disease Exclusion Criteria

  • Allergic or hypersensitivity to the IMU-838, Oseltamivir, or any of the ingredients
  • Pregnant or breastfeeding or with intention to become pregnant during the study
  • Participants who cannot take trial medication orally at presentation
  • Undergoing active chemotherapy or radiotherapy.
  • If the attending clinician believes that there is a specific contra-indication to the IONIC intervention.
  • Patient has a medical or concomitant disease history preventing them from participating
  • Critical patients whose expected survival time < 48-72 hours
  • Evidence of pancytopenia or immunosuppression
  • Any contraindication to Oseltamivir or standard of care

Presence of the following laboratory values at Screening Exclusion Criteria

  • Platelet count <100,000/mm³ (<100 x 109/L)
  • Total bilirubin > 2 x ULN or ALT or GGT > 5 x ULN
  • Elevated indirect (unconjugated) bilirubin >1.2 x ULN (i.e. >1.1 mg/dL)
  • Serum uric acid levels at Screening Visit >1.2 x ULN (for women >6.8 mg/dL, for men >8.4 mg/dL)
  • Renal impairment defined as estimated glomerular filtration rate ≤45 mL/min/1.73m²
  • Decompensated liver cirrhosis (Child-Pugh score B and C)
  • History or presence of serious or acute heart disease such as uncontrolled cardiac dysrhythmia or arrhythmia, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure (New York Heart Association [NYHA] class 3 or 4)
  • Cardiac disease resulting in marked limitation of physical activity. Patients are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain. NYHA class 4: Cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.
  • History or presence of any major medical or psychiatric illness (such as severe depression, psychosis, bipolar disorder), history of suicide attempt, or current suicidal ideation, if any of those conditions in the opinion of the investigator could create undue risk to the patient or could affect adherence with the trial protocol

COVID-19 related exclusion criteria

• Participation in any other interventional clinical trial for an experimental treatment for COVID-19


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04516915


Locations
Layout table for location information
United Kingdom
University Hospital Coventry and Warwickshire NHS Trust Recruiting
Coventry, West Midlands, United Kingdom, CV22DX
Contact: Kavi Sharma, MD    2476966197    kavi.sharma@uhcw.nhs.uk   
Contact: Chris Bradley, MSc    02476966581 ext 26581    christopher.bradley@uhcw.nhs.uk   
Principal Investigator: Ramesh Arasaradnam, PhD         
Sponsors and Collaborators
University Hospitals Coventry and Warwickshire NHS Trust
Immunic AG
University of Warwick
MODEPHARMA
Layout table for additonal information
Responsible Party: University Hospitals Coventry and Warwickshire NHS Trust
ClinicalTrials.gov Identifier: NCT04516915    
Other Study ID Numbers: RA486120
First Posted: August 18, 2020    Key Record Dates
Last Update Posted: August 21, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Oseltamivir
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action